

Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

<https://marketpublishers.com/r/G5D8F9A0F781EN.html>

Date: February 2023

Pages: 101

Price: US\$ 3,480.00 (Single User License)

ID: G5D8F9A0F781EN

Abstracts

Attention-deficit/hyperactivity disorder (ADHD) is a disorder marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development.

Inattention means a person wanders off task, lacks persistence, has difficulty sustaining focus, and is disorganized; and these problems are not due to defiance or lack of comprehension.

Hyperactivity means a person seems to move about constantly, including in situations in which it is not appropriate; or excessively fidgets, taps, or talks. In adults, it may be extreme restlessness or wearing others out with constant activity.

Impulsivity means a person makes hasty actions that occur in the moment without first thinking about them and that may have a high potential for harm, or a desire for immediate rewards or inability to delay gratification. An impulsive person may be socially intrusive and excessively interrupt others or make important decisions without considering the long-term consequences.

According to our (Global Info Research) latest study, the global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Attention-deficit

Hyperactivity Disorder (ADHD) Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market size and forecasts, in consumption value (\$ Million), 2018-2029

Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market size and forecasts by region and country, in consumption value (\$ Million), 2018-2029

Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market size and forecasts, by Type and by Application, in consumption value (\$ Million), 2018-2029

Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market shares of main players, in revenue (\$ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, GSK, Eli Lilly, Novartis and Johnson & Johnson, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation

Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Stimulants

Non-stimulants

Market segment by Application

Pediatric and Adolescents

Adults

Market segment by players, this report covers

Pfizer

GSK

Eli Lilly

Novartis

Johnson & Johnson

Mallinckrodt

Hisamitsu

UCB

Takeda

Purdue Pharma

Impax Laboratories

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Argentina and Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics, with revenue, gross margin and global market share of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics from 2018 to 2023.

Chapter 3, the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023. and Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War

Chapter 12, the key raw materials and key suppliers, and industry chain of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics.

Chapter 13, to describe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

1.2 Market Estimation Caveats and Base Year

1.3 Classification of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics by Type

1.3.1 Overview: Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029

1.3.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value Market Share by Type in 2022

1.3.3 Stimulants

1.3.4 Non-stimulants

1.4 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market by Application

1.4.1 Overview: Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029

1.4.2 Pediatric and Adolescents

1.4.3 Adults

1.5 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size & Forecast

1.6 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast by Region

1.6.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region: 2018 VS 2022 VS 2029

1.6.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region, (2018-2029)

1.6.3 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Prospect (2018-2029)

1.6.4 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Prospect (2018-2029)

1.6.5 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Prospect (2018-2029)

1.6.6 South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Prospect (2018-2029)

1.6.7 Middle East and Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Prospect (2018-2029)

2 COMPANY PROFILES

2.1 Pfizer

2.1.1 Pfizer Details

2.1.2 Pfizer Major Business

2.1.3 Pfizer Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions

2.1.4 Pfizer Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.1.5 Pfizer Recent Developments and Future Plans

2.2 GSK

2.2.1 GSK Details

2.2.2 GSK Major Business

2.2.3 GSK Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions

2.2.4 GSK Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.2.5 GSK Recent Developments and Future Plans

2.3 Eli Lilly

2.3.1 Eli Lilly Details

2.3.2 Eli Lilly Major Business

2.3.3 Eli Lilly Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions

2.3.4 Eli Lilly Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.3.5 Eli Lilly Recent Developments and Future Plans

2.4 Novartis

2.4.1 Novartis Details

2.4.2 Novartis Major Business

2.4.3 Novartis Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions

2.4.4 Novartis Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.4.5 Novartis Recent Developments and Future Plans

2.5 Johnson & Johnson

2.5.1 Johnson & Johnson Details

2.5.2 Johnson & Johnson Major Business

2.5.3 Johnson & Johnson Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

Product and Solutions

2.5.4 Johnson & Johnson Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.5.5 Johnson & Johnson Recent Developments and Future Plans

2.6 Mallinckrodt

2.6.1 Mallinckrodt Details

2.6.2 Mallinckrodt Major Business

2.6.3 Mallinckrodt Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

Product and Solutions

2.6.4 Mallinckrodt Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.6.5 Mallinckrodt Recent Developments and Future Plans

2.7 Hisamitsu

2.7.1 Hisamitsu Details

2.7.2 Hisamitsu Major Business

2.7.3 Hisamitsu Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions

2.7.4 Hisamitsu Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.7.5 Hisamitsu Recent Developments and Future Plans

2.8 UCB

2.8.1 UCB Details

2.8.2 UCB Major Business

2.8.3 UCB Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions

2.8.4 UCB Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.8.5 UCB Recent Developments and Future Plans

2.9 Takeda

2.9.1 Takeda Details

2.9.2 Takeda Major Business

2.9.3 Takeda Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions

2.9.4 Takeda Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.9.5 Takeda Recent Developments and Future Plans

2.10 Purdue Pharma

2.10.1 Purdue Pharma Details

2.10.2 Purdue Pharma Major Business

2.10.3 Purdue Pharma Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions

2.10.4 Purdue Pharma Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.10.5 Purdue Pharma Recent Developments and Future Plans

2.11 Impax Laboratories

2.11.1 Impax Laboratories Details

2.11.2 Impax Laboratories Major Business

2.11.3 Impax Laboratories Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions

2.11.4 Impax Laboratories Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.11.5 Impax Laboratories Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Share by Players (2018-2023)

3.2 Market Share Analysis (2022)

3.2.1 Market Share of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics by Company Revenue

3.2.2 Top 3 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Players Market Share in 2022

3.2.3 Top 6 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Players Market Share in 2022

3.3 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market: Overall Company Footprint Analysis

3.3.1 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market: Region Footprint

3.3.2 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market: Company Product Type Footprint

3.3.3 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market: Company Product Application Footprint

3.4 New Market Entrants and Barriers to Market Entry

3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

4.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption

Value and Market Share by Type (2018-2023)

4.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market
Forecast by Type (2024-2029)

5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption
Value Market Share by Application (2018-2023)

5.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market
Forecast by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics
Consumption Value by Type (2018-2029)

6.2 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics
Consumption Value by Application (2018-2029)

6.3 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market
Size by Country

6.3.1 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics
Consumption Value by Country (2018-2029)

6.3.2 United States Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics
Market Size and Forecast (2018-2029)

6.3.3 Canada Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market
Size and Forecast (2018-2029)

6.3.4 Mexico Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size
and Forecast (2018-2029)

7 EUROPE

7.1 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption
Value by Type (2018-2029)

7.2 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption
Value by Application (2018-2029)

7.3 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by
Country

7.3.1 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics
Consumption Value by Country (2018-2029)

7.3.2 Germany Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market

Size and Forecast (2018-2029)

7.3.3 France Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2018-2029)

7.3.4 United Kingdom Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2018-2029)

7.3.5 Russia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2018-2029)

7.3.6 Italy Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2018-2029)

8 ASIA-PACIFIC

8.1 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Type (2018-2029)

8.2 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Application (2018-2029)

8.3 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region

8.3.1 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Region (2018-2029)

8.3.2 China Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2018-2029)

8.3.3 Japan Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2018-2029)

8.3.4 South Korea Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2018-2029)

8.3.5 India Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2018-2029)

8.3.6 Southeast Asia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2018-2029)

8.3.7 Australia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2018-2029)

9 SOUTH AMERICA

9.1 South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Type (2018-2029)

9.2 South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Application (2018-2029)

9.3 South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country

9.3.1 South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Country (2018-2029)

9.3.2 Brazil Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2018-2029)

9.3.3 Argentina Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2018-2029)

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Type (2018-2029)

10.2 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Application (2018-2029)

10.3 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country

10.3.1 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Country (2018-2029)

10.3.2 Turkey Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2018-2029)

10.3.3 Saudi Arabia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2018-2029)

10.3.4 UAE Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Forecast (2018-2029)

11 MARKET DYNAMICS

11.1 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Drivers

11.2 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Restraints

11.3 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

11.5 Influence of COVID-19 and Russia-Ukraine War

11.5.1 Influence of COVID-19

11.5.2 Influence of Russia-Ukraine War

12 INDUSTRY CHAIN ANALYSIS

12.1 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Industry Chain

12.2 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Upstream Analysis

12.3 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Midstream Analysis

12.4 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

14.1 Methodology

14.2 Research Process and Data Source

14.3 Disclaimer

List Of Tables

LIST OF TABLES

- Table 1. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
- Table 2. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
- Table 3. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
- Table 4. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
- Table 5. Pfizer Company Information, Head Office, and Major Competitors
- Table 6. Pfizer Major Business
- Table 7. Pfizer Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
- Table 8. Pfizer Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 9. Pfizer Recent Developments and Future Plans
- Table 10. GSK Company Information, Head Office, and Major Competitors
- Table 11. GSK Major Business
- Table 12. GSK Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
- Table 13. GSK Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 14. GSK Recent Developments and Future Plans
- Table 15. Eli Lilly Company Information, Head Office, and Major Competitors
- Table 16. Eli Lilly Major Business
- Table 17. Eli Lilly Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
- Table 18. Eli Lilly Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 19. Eli Lilly Recent Developments and Future Plans
- Table 20. Novartis Company Information, Head Office, and Major Competitors
- Table 21. Novartis Major Business
- Table 22. Novartis Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
- Table 23. Novartis Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 24. Novartis Recent Developments and Future Plans

Table 25. Johnson & Johnson Company Information, Head Office, and Major Competitors

Table 26. Johnson & Johnson Major Business

Table 27. Johnson & Johnson Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions

Table 28. Johnson & Johnson Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 29. Johnson & Johnson Recent Developments and Future Plans

Table 30. Mallinckrodt Company Information, Head Office, and Major Competitors

Table 31. Mallinckrodt Major Business

Table 32. Mallinckrodt Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions

Table 33. Mallinckrodt Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 34. Mallinckrodt Recent Developments and Future Plans

Table 35. Hisamitsu Company Information, Head Office, and Major Competitors

Table 36. Hisamitsu Major Business

Table 37. Hisamitsu Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions

Table 38. Hisamitsu Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 39. Hisamitsu Recent Developments and Future Plans

Table 40. UCB Company Information, Head Office, and Major Competitors

Table 41. UCB Major Business

Table 42. UCB Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions

Table 43. UCB Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 44. UCB Recent Developments and Future Plans

Table 45. Takeda Company Information, Head Office, and Major Competitors

Table 46. Takeda Major Business

Table 47. Takeda Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions

Table 48. Takeda Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 49. Takeda Recent Developments and Future Plans

Table 50. Purdue Pharma Company Information, Head Office, and Major Competitors

Table 51. Purdue Pharma Major Business

- Table 52. Purdue Pharma Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
- Table 53. Purdue Pharma Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 54. Purdue Pharma Recent Developments and Future Plans
- Table 55. Impax Laboratories Company Information, Head Office, and Major Competitors
- Table 56. Impax Laboratories Major Business
- Table 57. Impax Laboratories Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product and Solutions
- Table 58. Impax Laboratories Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 59. Impax Laboratories Recent Developments and Future Plans
- Table 60. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (USD Million) by Players (2018-2023)
- Table 61. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Share by Players (2018-2023)
- Table 62. Breakdown of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)
- Table 63. Market Position of Players in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
- Table 64. Head Office of Key Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Players
- Table 65. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market: Company Product Type Footprint
- Table 66. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market: Company Product Application Footprint
- Table 67. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics New Market Entrants and Barriers to Market Entry
- Table 68. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Mergers, Acquisition, Agreements, and Collaborations
- Table 69. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value (USD Million) by Type (2018-2023)
- Table 70. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value Share by Type (2018-2023)
- Table 71. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value Forecast by Type (2024-2029)
- Table 72. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Application (2018-2023)

Table 73. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value Forecast by Application (2024-2029)

Table 74. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 75. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 76. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 77. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 78. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 79. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 80. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 81. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 82. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 83. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 84. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 85. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 86. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 87. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 88. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 89. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 90. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Region (2018-2023) & (USD Million)

Table 91. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Region (2024-2029) & (USD Million)

Table 92. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

Consumption Value by Type (2018-2023) & (USD Million)

Table 93. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 94. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 95. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 96. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 97. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 98. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 99. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 100. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 101. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 102. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 103. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 104. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Raw Material

Table 105. Key Suppliers of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Raw Materials

List Of Figures

LIST OF FIGURES

Figure 1. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Picture

Figure 2. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 3. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value Market Share by Type in 2022

Figure 4. Stimulants

Figure 5. Non-stimulants

Figure 6. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 7. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value Market Share by Application in 2022

Figure 8. Pediatric and Adolescents Picture

Figure 9. Adults Picture

Figure 10. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value, (USD Million): 2018 & 2022 & 2029

Figure 11. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value and Forecast (2018-2029) & (USD Million)

Figure 12. Global Market Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)

Figure 13. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value Market Share by Region (2018-2029)

Figure 14. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value Market Share by Region in 2022

Figure 15. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 16. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 17. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 18. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 19. Middle East and Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 20. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Share by Players in 2022

Figure 21. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022

Figure 22. Global Top 3 Players Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share in 2022

Figure 23. Global Top 6 Players Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share in 2022

Figure 24. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value Share by Type (2018-2023)

Figure 25. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share Forecast by Type (2024-2029)

Figure 26. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value Share by Application (2018-2023)

Figure 27. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share Forecast by Application (2024-2029)

Figure 28. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 29. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 30. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 31. United States Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 32. Canada Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 33. Mexico Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 34. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 35. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 36. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 37. Germany Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 38. France Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 39. United Kingdom Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 40. Russia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

Consumption Value (2018-2029) & (USD Million)

Figure 41. Italy Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

Consumption Value (2018-2029) & (USD Million)

Figure 42. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

Consumption Value Market Share by Type (2018-2029)

Figure 43. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

Consumption Value Market Share by Application (2018-2029)

Figure 44. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

Consumption Value Market Share by Region (2018-2029)

Figure 45. China Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

Consumption Value (2018-2029) & (USD Million)

Figure 46. Japan Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

Consumption Value (2018-2029) & (USD Million)

Figure 47. South Korea Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

Consumption Value (2018-2029) & (USD Million)

Figure 48. India Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

Consumption Value (2018-2029) & (USD Million)

Figure 49. Southeast Asia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

Consumption Value (2018-2029) & (USD Million)

Figure 50. Australia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

Consumption Value (2018-2029) & (USD Million)

Figure 51. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

Consumption Value Market Share by Type (2018-2029)

Figure 52. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

Consumption Value Market Share by Application (2018-2029)

Figure 53. South America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

Consumption Value Market Share by Country (2018-2029)

Figure 54. Brazil Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

Consumption Value (2018-2029) & (USD Million)

Figure 55. Argentina Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

Consumption Value (2018-2029) & (USD Million)

Figure 56. Middle East and Africa Attention-deficit Hyperactivity Disorder (ADHD)

Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 57. Middle East and Africa Attention-deficit Hyperactivity Disorder (ADHD)

Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 58. Middle East and Africa Attention-deficit Hyperactivity Disorder (ADHD)

Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 59. Turkey Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

Consumption Value (2018-2029) & (USD Million)

Figure 60. Saudi Arabia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 61. UAE Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 62. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Drivers

Figure 63. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Restraints

Figure 64. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Trends

Figure 65. Porters Five Forces Analysis

Figure 66. Manufacturing Cost Structure Analysis of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics in 2022

Figure 67. Manufacturing Process Analysis of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics

Figure 68. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Industrial Chain

Figure 69. Methodology

Figure 70. Research Process and Data Source

I would like to order

Product name: Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Product link: <https://marketpublishers.com/r/G5D8F9A0F781EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5D8F9A0F781EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

